Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
328.00
+2.36 (0.72%)
At close: Jul 24, 2025, 4:00 PM
329.00
+1.00 (0.30%)
After-hours: Jul 24, 2025, 6:17 PM EDT
Alnylam Pharmaceuticals Stock Forecast
Stock Price Forecast
The 25 analysts that cover Alnylam Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $347.75, which forecasts a 6.02% increase in the stock price over the next year. The lowest target is $220 and the highest is $500.
Price Target: $347.75 (+6.02%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Alnylam Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 11 | 11 | 12 | 11 | 13 |
| Buy | 8 | 9 | 9 | 9 | 8 | 8 |
| Hold | 4 | 3 | 3 | 3 | 3 | 3 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 23 | 24 | 24 | 25 | 23 | 25 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Initiates $385 | Strong Buy | Initiates | $385 | +17.38% | Jul 21, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $338 → $348 | Buy | Maintains | $338 → $348 | +6.10% | Jul 16, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $364 → $404 | Strong Buy | Maintains | $364 → $404 | +23.17% | Jul 11, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $336 → $359 | Strong Buy | Maintains | $336 → $359 | +9.45% | Jul 11, 2025 |
| Jefferies | Jefferies | Strong Buy Maintains $328 → $384 | Strong Buy | Maintains | $328 → $384 | +17.07% | Jul 7, 2025 |
Financial Forecast
Revenue This Year
2.98B
from 2.25B
Increased by 32.73%
Revenue Next Year
3.92B
from 2.98B
Increased by 31.50%
EPS This Year
-1.39
from -2.18
EPS Next Year
1.47
from -1.39
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.6B | 5.9B | 6.9B | ||
| Avg | 3.0B | 3.9B | 5.0B | ||
| Low | 2.4B | 2.8B | 3.5B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 60.2% | 97.8% | 76.9% | ||
| Avg | 32.7% | 31.5% | 26.8% | ||
| Low | 7.9% | -7.6% | -10.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.45 | 5.52 | 11.66 | ||
| Avg | -1.39 | 1.47 | 6.36 | ||
| Low | -2.29 | -3.11 | 1.48 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 691.3% | ||
| Avg | - | - | 332.1% | ||
| Low | - | - | 0.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.